Economic evidence and point-of-care testing

Clinical Biochemist Reviews

Volumn 34, Issue 2, 2013, Pages 61-74

  John, Andrew St ^a   Price, Christopher P ^b  

^a Australian Government Australian Research Council   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901978356     PISSN: 01598090     EISSN: 18380212     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health System. Washington DC: Institute of Medicine, National Academies Press; 2000. p. 1-287.
2. Australian Government Department of Health and Ageing. Pathology services to be better managed and funded, delivering $550 million saving to taxpayer. http://www.health.gov.au/internet/ministers/publishing.nsf/Content/mr-yrll-nr-nr065.htm?OpenDocument&yr=2011&mth=04 (Accessed 4 July 2013).
3. Birenbaum M.S.. Healthcare reform: dumping on Medicare Part B. Medical Laboratory Observer, February 2011. http://www.mlo-online.com/articles/201102/healthcare-reform-rn-dumping-on-medicare-part-b.php (Accessed 4 July 2013).
4. Beastall GH. The modernisation of pathology and laboratory medicine in the UK: networking into the future. Clin Biochem Rev, 2008;29:3-10.
5. Sarkozi L, Simson E, Ramanathan L. The effects of total laboratory automation on the management of a clinical chemistry laboratory. Retrospective analysis of 36 years. Clin Chim Acta, 2003;329:89-94.
6. Callahan D. Health care costs and medical technology. In: Crowley M, editor. From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns. Garrison, NY: The Hastings Center; 2008. p. 79-82.
7. Robert G, Greenhalgh T, MacFarlane F, Peacock R. Organisational factors influencing technology adoption and assimilation in the NHS: a systematic literature review. 2009. www.netscc.ac.uk/hsdr/files/project/SDO_FR_08-1819-223_V01.pdf (Accessed 4 July 2013).
8. Cutler DM. Where are the health care entrepreneurs? The failure of organizational innovation in health care, http://ideas.repec.org/p/nbr/nberwo/16030.html (Accessed 4 July 2013).
9. Council of the European Union. Council conclusions on innovation in the medical device sector. http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/122397.pdf (Accessed 4 July 2013).
10. Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q, 2005;83:691-729.
11. Medical Services Advisory Committee. Department of Health and Ageing, Australian Government, http://www.msac.gov.au/internet/msac/publishing.nsf/Content/guidelines-2012 (Accessed 4 July 2013).
12. Medical Technologies Evaluation Programme. National Institute for Health and Care Excellence, UK. http://www.nice.org.uk/aboutnice/whatwedo/aboutmedicaltechnologies/medicaltechnologiesprogramme.jsp (Accessed 4 July 2013).
13. Severens JL, van der Wilt G-J. Economic evaluation of diagnostic tests. A review of published studies. Int J Technol Assess Health Care, 1999;15:480-96.
14. Fang C, Otero HJ, Greenberg D, Neumann PJ. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health, 2011;14:1010-8.
15. Drummond MF, Sculphur MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2004. p. 1-396.
16. Scott MA, Raftery JP. Evidence-based laboratory medicine: health economics, reimbursement, and the value proposition. In: Price CP, Christenson RH, editors. Evidence-Based Laboratory Medicine. Second Edition. Washington DC: AACC Press; 2007. p. 321-45.
17. St John A, Price CP. Health economics and point of care testing. In: Price CP, St John A, Kricka LL, eds. Point of Care Testing. Third Edition. Washington DC: AACC Press; 2010. p. 267-78.
18. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ, 2002;324:539-41.
19. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ 2012;344:e686. doi:10.1136/bmj.e686.
20. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making, 1990;10:212-4.
21. National Institute for Health and Care Excellence. Glossary. http://www.nice.org.uk/website/glossary/glossary.jsp?alpha=C (Accessed 4 July 2013).
22. Kaufman R, Watkins R. Cost consequences analysis; a case study. Human Resources Development Quarterly, 1996;7:87-100.
23. Wilkinson D. Cost-benefit analysis versus cost-consequences analysis. Performance Improvement Quarterly, 1999;12:71-81.
24. Wilson JM, Junger G. Principles and practice of screening for disease. World Health Organization. Public Health Papers No 34. 1968. http://whqlibdoc.who.int/php/WHO_PHP_34.pdf (Accessed 4 July 2013).
25. Lord S J, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006;144:850-5.
26. Lord SJ, Irwig L, Bossuyt PM. Using the principles of randomized controlled trial design to guide test evaluation. Med Decis Making 2009;29:E1-12.
27. Price CP. Evidence-based laboratory medicine: is it working in practice? Clin Biochem Rev 2012;33:13-9.
28. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A; Diabetes Glycaemic Education and Monitoring Trial Group. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ, 2008;336:1177-80.
29. Sutton AJ, Cooper NJ, Goodacre S, Stevenson M. Integration of meta-analysis and economic decision modeling for evaluating diagnostic tests. Med Decis Making, 2008;28:650-67.
30. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ2007;335:132.
31. Claes N, Moeremans K, Frank B, Jef A, Jos V, Herman VL, et al. Estimating the cost-effectiveness of quality-improving interventions in oral anticoagulation management within general practice. Value Health, 2006;9:369-76.
32. Laurence CO, Moss JR Briggs NE, Beilby JJ; PoCT Trial Management Group. The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial. BMC Health Serv Res 2010;10:165.
33. Cals JW, Ament AJ, Hood K, Butler CC, Hopstaken RM, Wassink GF, et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract, 2011;17:1059-69.
34. Fitzgerald P, Goodacre SW, Cross E, Dixon S. Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel assay of cardiac markers (R ATP AC) trial. Acad Emerg Med, 2011;18:488-95.
35. Parry D, Fitzmaurice D, Raftery J. Anticoagulation management in primary care: a trial-based economic evaluation. Br JHaematol, 2000;111:530-3.
36. Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A, et al. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. BMJ, 2001;322:898-901.
37. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet, 2006;367:404-11.
38. Bubner TK, Laurence CO, Gialamas A, Yelland LN, Ryan P, Willson KJ, et al. Effectiveness of point-of-care testing for therapeutic control of chronic conditions: results from the PoCT in General Practice Trial. Med J Aust, 2009;190:624-6.
39. Goodacre SW, Bradburn M, Cross E, Collinson P, Gray A, Hall AS; RATPAC Research Team. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart, 2011;97:190-6.
40. Thokala P, Goodacre SW, Collinson PO, Stevens JW, Mills NL, Newby DE, et al. Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 2012;98:1498-503.
41. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11 :iii-iv, ix-66.
42. Gailly J, Gerkens S, Van Den Bruel A, Devriese S, Obyn C, Cleemput I. Use of point-of-care devices in patients with oral anticoagulation : a health technology assessment. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 117C. 2009.
43. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis, (iii-iv.) Health Technol Assess 2006;10:l-168,iii-iv.
44. Jowett S, Bryan S, Murray E, McCahon D, Raftery J, Hobbs FD, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol, 2006;134:632-9.
45. Kesavadev J, Shankar A, Pillai PB, Krishnan G, Jothydev S. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus-a retrospective study. Diabetes Technol Ther, 2012;14:772-6.
46. Kong MC, Lim TG, Ng HJ, Chan YH, Lee LH. Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic. AnnHematol, 2008;87:905-10.
47. Spalding GJ, Hartrumpf M, Sierig T, Oesberg N, Kirschke CG, Albes JM. Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM). Eur J Cardiothorac Surg, 2007;31:1052-7.
48. Mahieu L, Marien A, De Dooy J, Mahieu M, Mahieu H, Van Hoof V. Implementation of a multi-parameter Point-of-Care-blood test analyzer reduces central laboratory testing and need for blood transfusions in very low birth weight infants. Clin Chim Acta, 2012;413:325-30.
49. Apple FS, Chung AY, Kogut ME, Bubany S, Murakami MM. Decreasedpatient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit. Clin Chim Acta, 2006;370:191-5.
50. Mills JM, Harper J, Broomfield D, Templeton KE. Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. J Hosp Infect, 2011;77:248-51.
51. Hatamabadi HR, Abdalvand A, Safari S, Kariman H, Dolatabadi AA, Shahrami A, et al. Tetanus Quick Stick as an applicable and cost-effective test in assessment of immunity status. Am J Emerg Med, 2011;29:717-20.
52. Cameron C, Coyle D, Ur E, Klarenbach S. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ, 2010;182:28-34.
53. Palmer AJ, Dinneen S, Gavin JR 3rd, Gray A, Herman WH, Karter AJ. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin, 2006;22:861-72.
54. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Manag Care, 2008;14:131-40.
55. Pollock RF, Valentine WJ, Goodall G, Brandle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral antidiabetic agents. Swiss Med Wkly 2010;140:wl3103.
56. Weber C, Kocher S, Neeser K, Bartaskova D. Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective. Curr Med Res Opin, 2010;26:289-96.
57. Tunis SL. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings. Appl Health Econ Health Policy, 2011;9:351-65.
58. Rydzak CE, Goldie SJ. Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. Sex Transm Dis, 2008;35:775-84.
59. Vickerman P, Peeling RW, Terris-Prestholt F, Changalucha J, Mabey D, Watson-Jones D, et al. Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania. Sex Transm Infect 2006;82(SUPPL5):v38-43.
60. Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, Whitty CJ, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ, 2008;86:101-10.
61. Vickerman P, Watts C, Peeling RW, Mabey D, Alary M. Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers. Sex Transm Infect, 2006;82:403-12.
62. Doyle NM, Levison JE, Gardner MO. Rapid HIV versus enzyme-linked immunosorbent assay screening in a low-risk Mexican American population presenting in labor: a cost-effectiveness analysis. Am J Obstet Gynecol, 2005;193:1280-5.
63. Owusu-Edusei K Jr, Gift TL, Ballard RC. Cost-effectiveness of a dual non-treponemal/treponemal syphilis point-of-care test to prevent adverse pregnancy outcomes in sub-Saharan Africa. Sex Transm Dis, 2011;38:997-1003.
64. Aledort JE, Hook EW 3rd, Weinstein MC, Goldie SJ. The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis, 2005;32:425-36.
65. Hislop J, Quayyum Z, Flett G, Boachie C, Fraser C, Mowatt G Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. (iii-iv.) Health Technol Assess 2010;14:l-97,iii-iv.
66. Swain GR, McDonald RA, Pfister JR, Gradus MS, Sedmak GV, Singh A. Decision analysis: point-of-care Chlamydia testing vs. laboratory-based methods. Clin Med Res, 2004;2:29-35.
67. Fauli S, Thue G. Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia. Eur J Health Econ, 2008;9:221-8.
68. Udeh BL, Schneider JE, Ohsfeldt RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. Am J Med Sci, 2008;336:254-64.
69. Neuner JM, Hamel MB, Phillips RS, Bona K, Aronson MD. Diagnosis and management of adults with pharyngitis. A cost-effectiveness analysis. Ann Intern Med, 2003;139:113-22.
70. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis 2008; 14:267-74.
71. Sintchenko V, Gilbert GL, Coiera E, Dwyer D. Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results. J Clin Virol, 2002;25:15-21.
72. Gerkens S, Gailly J, Obyn C, Devriese S, Cleemput I. Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation. J Thromb Thrombolysis, 2012;34:300-9.
73. Ten Cate-Hoek AJ, Toll DB, Biiller HR, Hoes AW, Moons KG, Oudega R, et al. Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost, 2009;7:2042-9.
74. Sullivan A, Hueppchen NA, Satin AJ. Cost effectiveness of bedside fetal fibronectin testing varies according to treatment algorithm. J MaternFetal Med, 2001;10:380-4.
75. Ramsey SD, Veenstra DL, Garrison LP Jr, Carlson R, Billings P, Carlson J, et al. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care, 2006;12:197-202.
76. Lindor RA, Allocco SJ, Cheatham L, Cortese DA, Hall RF, Mangold WJ Jr, et al. Regulatory and reimbursement innovation. Sci Transl Med 2013;5:176cm3.
77. Garrison LP Jr, Bresnahan BW, Higashi MK, Hollingworth W, Jarvik JG Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement. Acad Radiol 2011;18:1109-14.
78. Khunti K, Stone MA, Burden AC, Turner D, Raymond NT, Burden M, et al. Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. Br J Gen Pract, 2006;56:511-7.
79. The Physician Consortium for Performance Improvement, American Medical Association, http://www.ama-assn.org/resources/doc/cqi/pcpi-outcome-measures-framework.pdf (Accessed 4 July 2013).